<DOC>
	<DOCNO>NCT01453933</DOCNO>
	<brief_summary>Treatment HIV-infection protease inhibitor associate high blood lipid high chance cardiovascular complication . The RASSTER study aim investigate effect switch protease inhibitor lopinavir/ritonavir raltegravir vessel wall function inflammation , activation immune system . hypothesize intervention parameter improve . Since decrease vessel wall function inflammation initial step process atherosclerosis , important know data treat HIV-infected patient .</brief_summary>
	<brief_title>RAltegravir Switch STudy : Effects Endothelial Recovery</brief_title>
	<detailed_description>Fixed dose combination lopinavir/ritonavir ( LPV/r ) widespread use antiretroviral drug belong class protease inhibitor ( PIs ) . PIs associate increase risk myocardial infarction . However , data available suggest increased level plasma lipid sole explanation observation . Treatment LPV/r might lead decrease endothelial function well , thus explain increase risk myocardial infarction besides increased plasma lipid . Raltegravir register antiretroviral drug know cardiovascular side effect . We hypothesize switch LPV/r raltegravir HIV-infected patient suppress plasma viral load ( &lt; 50 copies/ml ) lead improvement endothelial function . Objective : - First , assess effect switch lopinavir/ritonavir raltegravir endothelial function . - Second , assess effect intervention mention marker endothelial function ; immune activation ; chronic inflammation ; , plasma HIV-RNA cut-off 50 copies/ml .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Age ≥ 18 year HIV1 infection Treatment antiretroviral regimen contain lopinavir/ritonavir least previous 3 month No protease inhibitor besides lopinavir/ritonavir antiretroviral regimen Subjects must minimum period viral suppression ( plasma HIVRNA &lt; 50 copies/ml ) 6 month Subjects history virological failure antiretroviral therapy Results previous resistance test allow replacement lopinavir/ritonavir raltegravir CD4+ cell count &gt; 200 cells/µL Signed informed consent Pregnancy Breastfeeding Raltegravir hypersensitivity Treatment underlying malignancy Renal insufficiency require dialysis Acute decompensated chronic hepatitis ( ChildPugh score C ) Modification antiretroviral regimen previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Lopinavir/ritonavir</keyword>
</DOC>